MDMA-like behavioral effects of N-substituted piperazines in the mouse

Pharmacology Biochemistry and Behavior

Volumn 88, Issue 1, 2007, Pages 18-27

  Yarosh, H L ^a   Katz, E B ^a   Coop, A ^b   Fantegrossi, W E ^a  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Drug discrimination; Head twitch response; Locomotor activity; MDMA

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 METHOXYBENZYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; HEAD TWITCH; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBSTITUTION LINE;

ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; CUES; DATA INTERPRETATION, STATISTICAL; DISCRIMINATION (PSYCHOLOGY); DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MALE; MICE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERAZINES; STEREOISOMERISM;

ANIMALIA; MUS;

EID: 34548524064     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.06.007     Document Type: Article

References (38)

1. Baumann M.H., Clark R.D., Budzynski A.G., Partilla J.S., Blough B.E., and Rothman R.B. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 30 (2005) 550-560
2. Benkelfat C., Murphy D.L., Hill J.L., George D.T., Nutt D., and Linnoila M. Ethanol-like properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry 48 (1991) 383
3. Buydens-Branchey L., Branchey M., Fergeson P., Hudson J., and McKernin C. The meta-chlorophenylpiperazine challenge test in cocaine addicts: hormonal and psychological responses. Biol Psychiatry 41 (1997) 1071-1086
4. Campbell H., Cline W., Evans M., Lloyd J., and Peck A.W. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 6 (1973) 170-176
5. Colpaert F.C., and Janssen P.A.J. The head twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology 22 8 (1983) 993-1000
6. Conn P.J., and Sanders-Bush E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther 242 (1987) 552-557
7. Corne S.J., and Pickering R.W. A possible correlation between drug-induced hallucinations in man and a behavioral response in mice. Psychopharmacologia 11 (1967) 65-78
8. Corne S.J., Pickering R.W., and Warner B.T. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol 20 (1963) 106-120
9. 2 receptor-induced head-twitch behavior in mice. Eur J Pharmacol 186 (1990) 115-118
10. 2 receptors?. Pharmacol Biochem Behav 36 (1990) 901-906
11. Darmani N.A., Martin B.R., and Glennon R.A. Behavioral evidence for differential adaptation of the serotonergic system after acute and chronic treatment with (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) or ketanserin. J Pharmacol Exp Ther 262 2 (1992) 692-698
12. de Boer D., Bosman I.J., Hidvegi E., Manzoni C., Benko A.A., dos Reys L.J., et al. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 121 (2001) 47-56
13. Dews P.B. Behavioral tolerance. NIDA Res Monogr 18 (1978) 18-26
14. Fantegrossi W.E., Godlewski T., Karabenick R.L., Stephens J.M., Ullrich T., Rice K.C., et al. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 166 3 (2003) 202-211
15. Fantegrossi W.E., Woods J.H., Winger G., McMahon L.R., France C.P., Woolverton W.L., et al. Progress report from the testing program for stimulant and depressant drugs (2003). In: Dewey W.L. (Ed). Problems of Drug Dependence, 2003: Proceeding of the 65th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. (National Institute on Drug Abuse Research Monograph #184, pp. 205-231) (2004), U.S. Government Printing Office, Washington D.C.
16. Fantegrossi W.E., Kiessel C.L., Leach P.T., Martin C.V., Karabenick R.L., Chen X., et al. Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology 173 3-4 (2004) 270-277
17. Fantegrossi W.E., Winger G., Woods J.H., Woolverton W.L., and Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 77 2 (2005) 161-168
18. Fantegrossi W.E., Kiessel C.L., De la Garza II R., and Woods J.H. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology 181 3 (2005) 529-536
19. Fantegrossi W.E., Harrington A.W., Eckler J.R., Arshad S., Rabin R.A., Winter J.C., et al. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology 181 3 (2005) 496-503
20. Fantegrossi W.E., Harrington A.W., Kiessel C.L., Eckler J.R., Rabin R.A., Winter J.C., et al. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 83 1 (2006) 122-129
21. Goodwin G.M., and Green A.R. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol 84 3 (1985) 743-753
22. 2 receptor antagonist pirenperone. Neuropharmacology 22 (1983) 573-578
23. Grotewiel M.S., Chu H., and Sanders-Bush E. m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts. J Pharmacol Exp Ther 271 (1994) 1122-1126
24. Johanson C.E., Kilbey M., Gatchalian K., and Tancer M. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug Alcohol Depend 81 1 (2006) 27-36
25. Landry M.J. MDMA: a review of epidemiologic data. J Psychoactive Drugs 34 (2002) 163-169
26. McCann U.D., Eligulashvili V., Mertl M., Murphy D.L., and Ricaurte G.A. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 147 (1999) 56-65
27. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18 (1986) 305-313
28. Oberlander C., Euvrard C., Dumont C., and Boissier C.R. Circling behavior induced by dopamine releasers and/or uptake inhibitors during degeneration of the nigrostriatal pathway. Eur J Pharmacol 60 (1979) 163-170
29. Peroutka S.J., Lebovitz R.M., and Snyder S.H. Two distinct central serotonin receptors with different physiological functions. Science 212 (1981) 827-829
30. Pettibone D.J., and Williams M. Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 33 (1984) 1531-1535
31. Schechter M.D. Serotonergic-dopaminergic mediation of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Biochem Beh 31 (1988) 817-824
32. Schoeffter P., and Hoyer D. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist?. Naunyn-Schmiedebergs Arch Pharmakol 339 3 (1989) 675-683
33. Schuster C.R. Theoretical basis of behavioral tolerance: implications of the phenomenon for problems of drug abuse. NIDA Res Monogr 18 (1978) 4-17
34. 3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36 14 (1987) 2297-2303
35. Tancer M.E., and Johanson C.E. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 65 1 (2001) 97-101
36. Tancer M., and Johanson C.E. Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 72 1 (2003) 33-44
37. United States Department of Justice/Drug Enforcement Administration. System to Retrieve Information from Drug Evidence II (STRIDE) (2003)
38. Vollenweider F.X., Gamma A., Liechti M., and Huber T. Psychological and cardiovascular effects and short-term sequela of MDMA ('ecstasy') in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19 (1998) 241-251